Scientists could win back trust lost during the COVID-19 pandemic if they just showed a little intellectual humility, according to a study published Monday in Nature Human Behavior.

It's no secret that scientists—and the science generally—took a hit during the health crisis. Public confidence in scientists fell from 87 percent in April 2000 to a low of 73 percent in October 2023, according to survey data from the Pew Research Center. And the latest Pew data released last week suggests it will be an uphill battle to regain what was lost, with confidence in scientists only rebounding three percentage points, to 76 percent in a poll from October.

Building trust

The new study in Nature Human Behavior may guide the way forward, though. The study encompasses five smaller studies probing the perceptions of scientists' trustworthiness, which previous research has linked to willingness to follow research-based recommendations.

Read full article

Comments

If you need any inspiration for cutting loose and relaxing this weekend, look no further than a free-wheeling troop of monkeys that broke out of their South Carolina research facility Wednesday and, as of noon Friday, were still "playfully exploring" with their newfound freedom.

In an update Friday, the police department of Yemassee, SC said that the 43 young, female rhesus macaque monkeys are still staying around the perimeter of the Alpha Genesis Primate Research Facility. "The primates are exhibiting calm and playful behavior, which is a positive indication," the department noted.

The fun-loving furballs got free after a caretaker "failed to secure doors" at the facility.

Read full article

Comments

Pamela Goodwin has received hundreds of emails from patients asking if they should take a cheap, readily available drug, metformin, to treat their cancer.

It’s a fair question: Metformin, commonly used to treat diabetes, has been investigated for treating a range of cancer types in thousands of studies on laboratory cells, animals, and people. But Goodwin, an epidemiologist and medical oncologist treating breast cancer at the University of Toronto’s Mount Sinai Hospital, advises against it. No gold-standard trials have proved that metformin helps treat breast cancer—and her recent research suggests it doesn’t.

Metformin’s development was inspired by centuries of use of French lilac, or goat’s rue (Galega officinalis), for diabetes-like symptoms. In 1918, researchers discovered that a compound from the herb lowers blood sugar. Metformin, a chemical relative of that compound, has been a top type 2 diabetes treatment in the United States since it was approved in 1994. It’s cheap—less than a dollar per dose—and readily available, with few side effects. Today, more than 150 million people worldwide take the stuff.

Read full article

Comments

Enlarge (credit: Getty | Pavlo Gonchar)

A federal grand jury has indicted an embattled Alzheimer's researcher for allegedly falsifying data to fraudulently obtain $16 million in federal research funding from the National Institutes of Health for the development of a controversial Alzheimer's drug and diagnostic test.

Hoau-Yan Wang, 67, a medical professor at the City University of New York, was a paid collaborator with the Austin, Texas-based pharmaceutical company Cassava Sciences. Wang's research and publications provided scientific underpinnings for Cassava's Alzheimer's treatment, Simufilam, which is now in Phase III trials.

Simufilam is a small-molecule drug that Cassava claims can restore the structure and function of a scaffolding protein in the brain of people with Alzheimer's, leading to slowed cognitive decline. But outside researchers have long expressed doubts and concerns about the research.

Read 7 remaining paragraphs | Comments